Oxbryta

Active Ingredient(s): Voxelotor
FDA Approved: * November 25, 2019
Pharm Company: * GLOBAL BLOOD THERAPS
Category: Genetic Disorders

Voxelotor, sold under the brand name Oxbryta, is a medication used for the treatment of sickle cell disease.[1][2][3][4][5] Developed by Global Blood Therapeutics, voxelotor is the first hemoglobin oxygen-affinity modulator.[6] Voxelotor has been shown to have disease-modifying potential by increasing hemoglobin levels and decreasing hemolysis indicators in sickle cell patients.[7] ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Oxbryta 500 mg Oral Tablet, Film Coated
NDC: 72786-101
Labeler:
Global Blood Therapeutics Inc.